Pharmacodynamics Ganierlix is a synthetic peptide that works as an antagonist against gonadotropin-releasing hormone (GnRH) <unk>  acetate injection," 2009).<unk>  competitively blocks GnRH receptors on the pituitary gonadotroph, quickly resulting in the suppression of gonadotropin secretion. This suppression is easily reversed by discontinuation of<unk>  administration.<unk>  has a significantly higher receptor binding affinity (Kd = 0.4 nM) than GnRH (Kd = 3.6 nM). Pharmacokinetics When<unk>  is given to healthy adult females, steady-state serum concentrations are reached, on average, after three days <unk>  acetate injection," 2009). A study administering<unk>  to healthy adult females (n=15) found the mean (SD) elimination half-life (t1/2) to be 16.2(1.6) hours, volume of distribution/absolute bioavailability (Vd/F) 76.5(10.3) liters, maximum serum concentration (Cmax) 11.2(2.4) ng/mL, and the time until maximum concentration (tmax) 1.1(0.2) hours. One 250 µg injection of<unk>  resulted in a mean absolute bioavailability of 91.1%.
Ganirelix
Cobicistat
Migalastat
Oprelvekin
Vosoritide
Pravastatin
Fluvastatin
Lovastatin